Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
Stock Information for Black Diamond Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.